`1 min read
`Allergan to focus on Alphagan-P, discontinue Alphagan
`
`IRVINE, Calif. — Because of physicians’ acceptance of the glaucoma drug Alphagan P, Allergan will discontinue U.S.
`distribution of its older formulation, Alphagan, the company announced last week.
`
`Alphagan P (brimonidine) 0.15% is comparable in e cacy to Alphagan 0.2%, but is preserved with Purite. Company
`o cials said their research has shown that “a vast majority” of its physician customers prefer this newer formulation
`brimonidine over the older version that did not have the Purite preservative. Clinical trials have shown patients who
`receive Alphagan P have lower rates of certain adverse events (such as ocular allergy) than patients receiving Alphaga
`
`Read next
`Pro ciency, exibility help match patients with appropriate MIGS device
`
`Three studies a rm e cacy, safety of brolucizumab in DME
`
`Both drugs are indicated for lowering intraocular pressure in patients with open-angle glaucoma and ocular
`hypertension.
`
`February 08, 2022
`1 min read
`TearClear initiates phase 3 trial of preservative-free latanoprost
`
`TearClear has initiated a phase 3 trial evaluating TC-002, a preservative-free latanoprost ophthalmic solution, in pati
`with glaucoma, according to a press release.
`
`The prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, 3-month CLEAR study
`investigating the ocular hypotensive e cacy and safety of TC-002 (preservative-free latanoprost ophthalmic solutio
`0.005%) compared with latanoprost ophthalmic solution 0.005%.
`
`CONTINUE READING
`
`